Skip to main content
Figure 1 | Microbial Cell Factories

Figure 1

From: Identification of myxobacteria-derived HIV inhibitors by a high-throughput two-step infectivity assay

Figure 1

Overview of the HIV screen assay. (A) Two step infection approach used for the primary screen. In Part 1, TZM-bl cells are seeded on 384-well plates, incubated with the test compounds for 2 h and infected with HIV. 48 h post-infection, supernatants from infected cells are used to infect fresh TZM-bl cells (beginning of Part 2). Cells from Part 1 are assayed for Tat-dependent luciferase expression and, in parallel, for compound-related toxicity. 48 h after re-infection, cells of Part 2 are assayed in the same manner (See text for details). (B) Scheme showing the possible outcomes of the two-step HIV screen. A compound inactive against HIV will not show significant reductions in Tat-dependent luciferase expression compared to solvent controls for both Part 1 and Part 2 of the screen (left). A compound truly acting on early steps of the HIV cycle will show reductions in luciferase expression in Part 1 that will be reflected in Part 2 of the screen (middle). A compound acting on late events might show little or no decrease in relative luciferase in Part 1, but it will show a significant reduction of luciferase expression in cells assayed in Part 2.

Back to article page